<DOC>
	<DOCNO>NCT00484276</DOCNO>
	<brief_summary>The main objective trial document progression free survival ( PFS ) advance metastatic malignant pleural mesothelioma patient treat NGR-hTNF single agent . Safety establish clinical laboratory assessment accord NCI-CTC criterion .</brief_summary>
	<brief_title>Study NGR-hTNF Single Agent Patients Affected Advanced Metastatic Malignant Pleural Mesothelioma</brief_title>
	<detailed_description>This phase II , open-label , non-randomized study conduct patient affect advanced metastatic malignant pleural mesothelioma previously treat one systemic therapeutic regimen , conduct use Simon 's two-stage design method .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>Patients &gt; 18 year affect malignant pleural mesothelioma previously treat one systemic therapeutic regimen Histologically cytological confirm malignant pleural mesothelioma follow subtype : epithelial , sarcomatous , mixed Prior intrapleural cytotoxic agent include bleomycin consider systemic chemotherapy ECOG Performance status 0 2 Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2.5 x ULN absence liver metastasis AST and/or ALT &lt; 5 x ULN presence liver metastasis Serum creatinine &lt; 1.5 x ULN Absence condition hypervolemia consequence ( e.g . increase stroke volume , elevate blood pressure ) haemodilution could represent risk patient ( take reference `` Technical data sheet human albumin '' specifically use Pharmacy Department NGRhTNF dilution ) Patients may prior therapy provide follow condition meet : Chemotherapy radiotherapy : washout period 28 day Surgery : washout period 14 day Normal cardiac function absence uncontrolled hypertension Patients must give write informed consent participate study Concurrent anticancer therapy Patients may receive investigational agent study Clinical sign CNS involvement Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction human albumin preparation excipients Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation . Patients male female reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>malignant pleural mesothelioma</keyword>
</DOC>